Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/17971
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | ARAIN, Amber | - |
dc.contributor.author | ROBAEYS, Geert | - |
dc.date.accessioned | 2014-12-15T13:00:50Z | - |
dc.date.available | 2014-12-15T13:00:50Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | WORLD JOURNAL OF GASTROENTEROLOGY, 20 (36), p. 12722-12733 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | http://hdl.handle.net/1942/17971 | - |
dc.description.abstract | In this decade, an increase is expected in end-stage liver disease and hepatocellular carcinoma, most commonly caused by hepatitis C virus (HCV) infection. Although people who inject drugs (PWID) are the major source for HCV infection, they were excluded from antiviral treatments until recently. Nowadays there is incontrovertible evidence in favor of treating these patients, and substitution therapy and active substance use are no longer contraindications for antiviral treatment. The viral clearance in PWID after HCV antiviral treatment with interferon or pegylated interferon combined with ribavirin is comparable to the viral clearance in non-substance users. Furthermore, multidisciplinary approaches to delivering treatment to PWID are advised, and their treatment should be considered on an individualized basis. To prevent the spread of HCV in the PWID community, recent active PWID are eligible for treatment in combination with needle exchange programs and substitution therapy. As the rate of HCV reinfection is low after HCV antiviral treatment, there is no need to withhold HCV treatment due to concerns about reinfection alone. Despite the advances in treatment efficacies and data supporting their success, HCV assessment of PWID and initiation of antiviral treatment remains low. However, the proportion of PWID assessed and treated for HCV is increasing, which can be further enhanced by understanding the barriers to and facilitators of HCV care. Removing stigmatization and implementing peer support and group treatment strategies, in conjunction with greater involvement by nurse educators/practitioners, will promote greater treatment seeking and adherence by PWID. Moreover, screening can be facilitated by noninvasive methods for detecting HCV antibodies and assessing liver fibrosis stages. Recently, HCV clearance has become a major endpoint in the war against drugs for the Global Commission on Drug Policy. This review highlights the most recent evidence concerning HCV infection and treatment strategies in PWID. (C) 2014 Baishideng Publishing Group Inc. All rights reserved. | - |
dc.description.sponsorship | Supported by Limburg Clinical Research Program (LCRP) and by the Limburg Sterk Merk Foundation of Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.rights | © 2014 Baishideng Publishing Group Inc. All rights reserved. | - |
dc.subject.other | Hepatitis C virus; persons who inject drugs; methadone; sustained viral response; adherence | - |
dc.subject.other | Hepatitis C virus; Persons who inject drugs; Methadone; Sustained viral response; Adherence | - |
dc.title | Eligibility of persons who inject drugs for treatment of hepatitis C virus infection | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 12733 | - |
dc.identifier.issue | 36 | - |
dc.identifier.spage | 12722 | - |
dc.identifier.volume | 20 | - |
local.format.pages | 12 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Arain, Amber; Robaeys, Geert] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, B-3600 Genk, Belgium. [Arain, Amber; Robaeys, Geert] Hasselt Univ, Fac Med & Life Sci, B-3590 Diepenbeek, Belgium. [Robaeys, Geert] UZ Leuven, Dept Hepatol, B-3000 Leuven, Belgium. | - |
local.publisher.place | PLEASANTON | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.3748/wjg.v20.i36.12722 | - |
dc.identifier.isi | 000343880900002 | - |
item.fullcitation | ARAIN, Amber & ROBAEYS, Geert (2014) Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. In: WORLD JOURNAL OF GASTROENTEROLOGY, 20 (36), p. 12722-12733. | - |
item.validation | ecoom 2015 | - |
item.contributor | ARAIN, Amber | - |
item.contributor | ROBAEYS, Geert | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 1007-9327 | - |
crisitem.journal.eissn | 2219-2840 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
arian 1.pdf | Published version | 821.6 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
16
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
21
checked on Jul 19, 2024
Page view(s)
108
checked on Jun 22, 2022
Download(s)
160
checked on Jun 22, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.